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Abstract: 
Solid lipid nanoparticles (SLN) are colloidal carrier systems representing a promising 
approach as a drug delivery system for topical application. Therefore, the objective of this 
investigation was to develop Meloxicam Solid lipid nanoparticles (MLX SLNs)   for topical delivery   
The present study addresses the influence of different formulation compositions as lipid type and 
concentration in addition to surfactant concentration on the physicochemical properties and drug 
release profile of MLX SLNs. The nanoparticles were developed by modified high shear 
homogenization and ultrasonication technique using Geleol, Compritol 888 ATO or Precirol ATO 5 
as solid core and poloxamer 188 as a surfactant. The results of the study revealed that MLX loaded 
SLNs showed extremely spherical shape having enriched core drug loading pattern with particle size 
(LD 90%) in the range of 325 to 1080 nm. A relatively high drug entrapment efficiency ranging from 
61.94 to 85.33 % was obtained with zeta potential values lie between -17.6 to -38.6 mV indicating 
good stability. DSC examination revealed that MLX encapsulated in SLNs was in the amorphous 
state. According to the rheological study, all nanoparticulate systems exhibited non-Newtonian 
pseudoplastic flow with thixotropic behavior.  In vitro release study showed a sustained release of 
MLX from the SLNs up to 48 h following Higuchi or zero order equations. Results of stability 
evaluation showed a long-term stability after storage at 4 ◦C for 12 months. In conclusion, SLNs with 
excellent physical stability, high entrapment efficiency and controlled drug release can be produced 
representing a promising carrier for topical delivery of meloxicam. 
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Introduction 
 During the recent decades several studies have suggested that novel drug delivery systems 
based on lipid nanoparticles have the potential of increasing cutaneous drug delivery of both 
hydrophilic and lipophilic, compared to the other conventional vehicles (Mandawgade and Patravale, 
2008; Liu et al., 2007a).  
 Solid lipid nanoparticles (SLNs)  are colloidal carrier systems composed of a high melting 
point lipid/s as a solid core coated by surfactants (Mehnert and Mader, 2001; Wissing et al., 2004). 
Distinct advantages of solid lipid nanoparticles include negligible skin irritation, controlled release 
and protection of active substances (Jenning and Gohla, 2001; Mei et al. 2003; Jee et al., 2006; Muller 
et al., 2008). Because they are composed of physiologically tolerated, non-irritative and non-toxic 
lipids, SLNs seem to be well suited for use on inflamed and damaged skin (Muller et al., 2000). 
Moreover, the small size of the lipid particles ensures close contact to the stratum corneum increasing 
the amount of the drug penetrating into the mucosa or skin (Jenning et al., 2000a). These nanometer 
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sized particles with their solid lipid matrix may also allowing for sustained drug release (Cevc, 2004; 
Schafer-Korting et al., 2007).. After topical application, occlusive properties were also reported which 
decreases transepidermal water loss and favors the drug penetrating through the stratum corneum 
(Wissing and Muller, 2003; Muller et al., 2002; Wissing et al., 2001). 
 Meloxicam (MLX), a non-steroidal anti-inflammatory drug (NSAID), is a preferential 
inhibitor of cycloo-xygenase-2 and has demonstrated potent analgesic and anti-inflammatory activity 
(Noble and Balfour, 1996). Considering the fact that most inflammatory diseases occur locally, 
topical application of MLX on the inflamed site can offer the advantage of delivering the drug directly 
producing its local effect. This occurs by avoiding gastric irritation, obtaining a substantial reduction 
of the systemic side effects, in addition to improvement of the patient compliance. In view of the 
characteristics of MLX including small oral dosage (7.5-15 mg/day), low molecular weight (354.1), 
lipid solubility and excellent tissue tolerability (Parfitt, 1999), it seems that there is a great need for 
investigating the MLX topical delivery system as an additional route for MLX administration. MLX 
performs very poorly in aqueous solubility and wettability, leading to difficulties in the design of 
pharmaceutical formulations. In order to overcome the formulation problems of MLX in addition to 
the barrier properties of the intact skin which limit the permeability of wide variety of pharmaceutical 
active agents, the development of a suitable vehicle system for optimum topical delivery of MLX is 
required. 
 Thus, the aim of the present study is to make the most benefits of solid lipid nanoparticles as 
drug delivery system for MLX through developing Meloxicam loaded Solid lipid nanoparticles (MLX 
SLNs) using high shear homogenization and ultrasonication method. Furthermore, the influence of 
some formulation variables on the characteristics of the MLX SLNs were also investigated. 
Materials and methods 
Materials 
 Meloxicam was supplied by Medical Union Pharmaceuticals, Abu-Sultan, Ismailia, Egypt. 
Geleol (glyceryl monostearate 40-55; 40–55 % monoglycerides - 30-45% diglyceride, m.p. 54.5-58.5 
oC), Compritol 888 ATO (glyceryl behenate; 15-23 % monoglycerides - 40-60% diglyceride - 21-35% 
triglycerides, m.p. 69.0-74.0 oC) and Precirol ATO5 (glyeryl palmitostearate; 8-22 % monoglycerides 
- 40-60 % diglyceride - 25-35 % triglycerides m.p. 50-60 oC), kindly donated by Gattefossé, France. 
Poloxamer 188 (Pluronic® F68; a triblock copolymer of polyoxyethylene-polyoxypropylene), 
Methanol, Chromasolv® and Dialysis tubing cellulose membrane (molecular weight cut-off 12,000 
g/mole) were purchased from Sigma Chemical Company, St. Louis, USA. All other chemicals and 
reagents used are of analytical grade. 
Methods 
Preparation of solid lipid nanoparticles 
 Solid lipid nanoparticles were prepared by a slight modification of the previously reported 
high shear homogenization and ultrasonication method (Mehnert and Mader, 2001; Venkateswarlu 
and Manjunath, 2004, 2005). Briefly, the lipid phase consisted of Geleol, Compritol or Precirol as 
solid lipid was melted 5 °C above the melting point of the lipid used and MLX (0.5% w/w) was 
dissolved therein to obtain a drug-lipid mixture. An aqueous phase consists of poloxamer 188 was 
heated up to the same temperature of the molten lipid phase. The hot lipid phase was poured onto the 
hot aqueous phase and homogenization was carried out at 25000 rpm for 5 minutes using Heidolph 
homogenizer (Heidolph Instruments, Germany). The resulted hot oil in water emulsion was sonicated 
for 30 minutes (Digital sonicator, MTI, USA). MLX loaded solid lipid nanoparticles were finally 
obtained by allowing hot nanoemulsion to cool to room temperature. Blank SLNs were prepared using 
the same procedure variables. 
MLX entrapment efficiency  
 The entrapment efficiency percent (E.E. %), which corresponds to the percentage of MLX 
encapsulated within the nanoparticles, was determined by measuring the concentration of free MLX 
in the dispersion medium. The unentrapped MLX was determined by adding 500 µl of MLX loaded 
nanoparticles to 9.5 ml methanol and then this dispersion was centrifuged at 9000 rpm (Union 32R, 
Hanil Science Industrial, Korea) for 30 minutes. The supernatant was filtered through millipore 
membrane filter (0.2 μm) and analyzed for unencapsulated MLX at 360 nm by using validated UV-
spectrophotometric method (Shimadzu, model 2401/PC, Japan) after suitable dilution. 
 The E.E. % was calculated using the following equation (Hou et al., 2003; Souto et al., 2004):  
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W initial drug – W free drug 
                      E.E. % =                          x 100 
                                                 W initial drug  
 Where “W initial drug” is the mass of initial drug used and the “W free drug” is the mass of free drug 
detected in the supernatant after centrifugation of the aqueous dispersion.   
Particle size analysis 
 Particle size analysis of MLX loaded nanoparticles was performed by Laser diffraction 
particle size analyzer (LD, Master sizer X, Malvern Instruments, UK) at 25°C. The LD data obtained 
were evaluated using volume distribution as diameter values of 10%, 50%, 90% and Span values. The 
diameter values indicate the percentage of particles possessing a diameter equal to or lower than the 
given value. The Span value is a statistical parameter useful to evaluate the particle size distribution, 
the lower the Span the narrower is the particle size distribution. It is calculated applying the following 
equation (Teeranachaideekul et al., 2007):   
                      LD 90% - LD 10% 
 Span =  
                              LD 50% 
Zeta potential (ξ) and pH measurement 
 Zeta potential was measured in folded capillary cells using Laser Zetameter (Malvern 
Instruments, UK). Measurements were performed in distilled water adjusted with a solution of 0.1mM 
NaCl at 25 °C. The zeta potential values were calculated using the Smoluchowski equation. 
 The pH values of MLX lipid nanoparticles were measured at 25°C using digital pH meter 
(Jenway, UK).  
Transmission Electron Microscopy (TEM) 
 The morphological examination MLX loaded SLNs was performed with TEM (model JEM-
1230, Jeol, Tokyo, Japan). One drop of diluted sample was deposited on the surface of carbon coated 
copper grid and negatively stained with a drop of 2 % (w/w) aqueous solution of phosphotungestic 
acid for 30 s. Excess staining solution was wiped off by filter paper, leaving thin aqueous film on the 
surface. After being stained, samples were allowed to dry at room temperature for 10 minutes for 
investigation (Li et al., 2006).  
Differential scanning calorimetry (DSC) analysis 
 DSC analysis was performed using Shimadzu Differential Scanning Calorimeter (DSC-50, 
Kyoto, Japan). About 10 mg sample was added in a 40 µl aluminium pan which was sealed and 
heated in the range of 30-300°C at a heating rate of 10°C /min. An empty aluminium pan was used as 
reference standard. Analysis was carried out under nitrogen purge. 
Rheological study 
 The rheological properties of the prepared lipid nanoparticles were measured using 
Brookfield’s viscometer (Brookfield LV-DV II+, USA). The sample (20 g) was placed in a beaker 
and allowed to equilibrate for 5 min. The measurements were carried at ambient temperature using the 
suitable spindle. The spindle speed rate was increased in ascending order from 1 to 100 rpm and then 
in descending order speed setting from 100 to 1 rpm with each kept constant for 10 seconds before a 
measurement was made. 
In vitro release study 
 In vitro release of meloxicam was evaluated by the dialysis bag diffusion technique reported 
by Yang, et al. (Yang et al., 1999). The release studies of meloxicam from solid lipid nanoparticles 
were performed in phosphate buffer pH 5.5 and methanol (75: 25). The aqueous nanoparticulate 
dispersion equivalent to 2 mg of meloxicam was placed in a cellulose acetate dialysis bag and sealed 
at both ends. The dialysis bag was immersed in the receptor compartment containing 50 ml of 
dissolution medium, which was stirred in a water bath shaker at 100 rpm (Memmert GmbH, 
Germany) and maintained at 32 ± 2°C. The receptor compartment was covered to prevent the 
evaporation of dissolution medium. A 2 ml sample of the receiver medium was withdrawn at 
predetermined time intervals (0.5, 1, 2, 3, 4, 5, 6, 8, 24 and 48 h) replaced by equivalent volume of 
fresh medium to maintain constant volume. The samples were analyzed for drug content 
spectrophotometrically at 360.5 nm. The data was analyzed using linear regression equations and the 
order of drug release from the different formulations was determined (zero order, first order or 
Higuchi diffusion model).                   
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Effect of storage on particle size 
 MLX loaded SLN formulations were stored at 4°C for 12 months. Particle size was 
determined  using Laser diffraction particle size analyzer (LD). 
Statistical analysis 
 All experiments were repeated three times and data were expressed as the mean value ± S.D. 
The statistical analysis of data was determined using one-way analysis of variance (ANOVA). 
Individual differences were evaluated using a nonparametric post hoc test. A difference of p < 0.05 
was considered to be statistically significant. 
Results and discussion 
Preparation of Solid lipid nanoparticles 
 SLNs have been prepared in various researches using different methods (Hu et al., 2002; 
Priano et al., 2007; Lva et al., 2009). In the present study, we had adopted an economical, simple and 
reproducible method for the preparation of SLN, i.e. homogenization followed by ultrasonication at 
above the melting point of the lipid (Fang et al., 2008; Chen et al., 2010). MLX loaded SLNs 
dispersions were composed of Geleol, Compritol 888 ATO or Precirol ATO 5 as core matrices used in 
different concentrations 5, 7.5 and 10 % (w/w). These lipid based carrier systems were stabilized by 
0.5, 1, 2.5 and 5 % (w/w) Poloxamer 188. Meloxicam was incorporated at a constant concentration of 
0.5% (w/w). The w/w percent composition of the investigated MLX SLNs is shown in table 1. 
Table I. Composition of MLX SLNs (%w/w) of different lipids 
MLX entrapment efficiency 
 The entrapment efficiencies of all SLN formulations are shown in table 2. The data clearly 
shows that all formulations possessed high entrapment efficiency (E.E. %) ranged from 61.94 ± 1.31 
to 85.33 ± 1.07 %. The results might be related to the structure of the lipid which had a great influence 
on the capacity for drug incorporation. Lipids which form highly crystalline particles with a perfect 
lattice (e.g. monoacid triglycerides) lead to drug expulsion (Westesen et al., 1997). More complex 
lipids as Geleol, Compritol 888 ATO and Precirol ATO 5; being mixtures of mono-, di- and 
triglycerides form less perfect crystals with many imperfections offering space to accommodate the 
drugs (Muller et al., 2000). The data clearly shows that Geleol SLNs exhibited the lowest entrapment 
of meloxicam compared to Compritol and Precirol SLNs (Figs. 1 and 2). This can be attributed to the 
difference in composition and chain length of the three lipids used. The higher drug E.E % noticed 
with Compritol and Precirol was attributed to the high hydrophobicity due to the long chain fatty 
acids attached to the triglycerides resulting in increased accommodation of lipophillic drugs (Jenning 
and Ghola, 2000).  
Formula  
Lipid Surfactant conc. 
(Poloxamer 188) (%) Type Conc. (%) 
SLN1 
Geleol 
5 
0.5 
SLN2 1 
SLN3 2.5 
SLN4 5 
SLN5 7.5 0.5 
SLN6 10 
SLN7 
Compritol 
5 
0.5 
SLN8 1 
SLN9 2.5 
SLN10 5 
SLN11 7.5 0.5 
SLN 12 10 
SLN 13 
Precirol 
5 
0.5 
SLN 14 1 
SLN 15 2.5 
SLN 16 5 
SLN17 7.5 0.5 
SLN18 10 
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 As observed in Fig. 1, at a constant amount of Poloxamer 188 (0.5 % w/w) increasing the 
lipid concentration from 5 to 7.5 % (w/w) resulted in a consequent increase in E.E. % (p<0.05), while 
decreased upon further lipid increase to 10 % (w/w). This is in accordance with the study done by 
Abdelbary and Fahmy on diazepam-loaded SLN, in which they found that increasing the Compritol 
concentration to 10% (w/w) consequently resulted in a decrease in the amount of diazepam entrapped. 
A possible explanation is that during the crystallization of the lipid phase a partial expulsion of the 
drug on the particle surface may occur. Furthermore, the higher viscosity at the interface produced by 
higher lipid concentration may cause a decrease in diffusion and hence fewer lipid molecules will be 
carried into the aqueous phase. Therefore, the formation and stabilization of lipid aggregates at these 
higher concentrations are reduced (Abdelbary and Fahmy, 2009). 
1st Annual International Interdisciplinary Conference, AIIC 2013, 24-26 April, Azores, Portugal        - Proceedings- 
784 
 
Table II. Physicochemical characterization of the MLX loaded SLNs
Formula LD 10 LD 50 LD 90 Span E.E % Z potential 
(ζ) (mV) pH 
SLN1 235 ± 53.03 350 ± 56.57 525 ± 35.36 0.83 70.00 ± 0.82 -19.0 5.50 ± 0.68 
SLN2 260 ± 28.28 350 ± 14.14 420 ± 14.14 0.46 65.67 ± 0.26 -20.3 6.03 ± 0.14 
SLN3 210 ± 30.90 270 ± 42.43 325 ± 7.07 0.43 62.07 ± 2.17 -23.7 6.39 ± 0.23 
SLN4 150 ± 14.14 230 ± 28.28 335 ± 7.07 0.80 61.94 ± 1.31 -24.7 5.60 ± 0.02 
SLN5 235 ± 77.78 405 ± 53.03 755 ± 21.21 1.28 72.08 ± 0.60 -27.2 5.88 ± 0.02 
SLN6 185 ± 7.07 385 ± 35.36 850 ± 28.28 1.73 67.03 ± 0.30 -38.2 5.40 ± 0.02 
        
SLN7 195 ± 7.07 395 ± 21.21 680 ±14.14 1.23 76.60 ± 0.88 -18.7 5.37 ± 0.17 
SLN8 205± 3.54 405 ± 7.07 585 ± 7.07 0.94 73.18  ± 0.24 -17.6 5.37 ± 0.02 
SLN9 215± 25.80 355 ± 77.78 475 ± 21.21 0.73 71.22 ± 0.56 -22.9 6.10 ± 0.05 
SLN10 235± 20.21 300 ± 70.71 415 ± 7.07 0.60 66.74 ± 0.16 -22.9 5.92 ± 0.04 
SLN11 185± 7.07 395 ± 21.21 1025± 21.21 2.13 80.96 ± 0.68 -22.8 6.33 ± 0.06 
SLN12 375± 75.77 505 ± 70.50 1080 ± 14.14 1.40 75.88 ± 0.91 -37.8 6.21 ± 0.09 
        
SLN13 190 ± 14.14 380 ± 56.57 675 ± 35.36 1.28 82.22 ± 0.39 -20.5 6.05 ± 0.23 
SLN14 185 ± 7.07 355 ± 7.07 565 ± 7.07 1.07 79.29 ±  0.90 -23.3 6.07 ± 0.02 
SLN15 155 ± 3.54 270 ± 14.14 440 ± 14.14 1.06 74.73 ± 1.68 -23.1 5.82 ± 0.29 
SLN16 145 ± 7.07 220 ± 14.14 325 ± 21.21 0.82 72.94 ± 2.99 -28.9 5.69 ± 0.15 
SLN17 185 ± 21.21 335 ± 7.07 1005 ± 35.36 2.45 85.33 ± 1.07 -32.1 5.77 ± 0.08 
SLN18 385 ± 50.91 515 ± 33.35 1000 ± 28.28 1.19 84.12 ± 0.94 -38.6 5.37 ± 0.06 
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Fig.1. Effect of lipid concentration and type on the E.E% of MLX SLNs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2. Effect of surfactant concentration on the E.E% of MLX SLNs  
 
It was also evident that increasing the amount of surfactant from 0.5, 1, 2.5 to 5 % (w/w) at a 
constant amount of lipid (5 % w/w), resulted in a gradual significant decrease in the E.E. % of the 
produced SLNs (p<0.05) (Fig. 2). This observed decrease in E.E. % could be explained by partition 
phenomenon. High surfactant level in the external phase might increase the partition of drug from 
internal to external phase of the medium. This increased partition is due to the increased solubilization 
of the drug in the external aqueous phase so more drug can disperse and dissolve in it (Rahman et al., 
2010). However, in case of Geleol SLNs no further decrease in E.E. % was observed upon increasing 
the poloxamer 188 concentration above 2.5% (w/w) (p>0.05) suggesting that an optimum 
concentration of surfactant was reached sufficient to cover the surface of nanoparticles effectively.  
Particle size analysis 
 Table 2 depicts LD data of resulting MLX SLNs where LD 90% was used for comparing the 
influence of different parameters on the size of the nanoparticles. The LD 90% of all formulations 
ranged from 325 ± 7.07 to 1080 ± 14.14 nm with low Span values indicating narrow particle size 
distribution. The results clearly showed that there was a gradual decrease in particle size with an 
increase in surfactant concentration from 0.5, 1, 2.5 to 5 % (w/w) (p0<0.5) (Fig. 3). This decrease in 
size at high surfactant concentrations might be due to effective reduction in interfacial tension 
between the aqueous and lipid phases leading to the formation of emulsion droplets of smaller size 
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(Liu et al., 2007b). Higher surfactant concentrations effectively stabilized the particles by forming a 
steric barrier on the particle surface and thereby protect smaller particles and prevent their 
coalescence into bigger ones (Rahman et al., 2010).   
As revealed in Figs. 3 and 4, Compritol 888 ATO showed the largest particle sizes followed 
by Precirol ATO 5 then Geleol SLNs. A possible explanation for the differences in sizes may be due 
to differences in chain lengths and viscosities of lipids used (Ahlin et al., 1998). Compritol 888 ATO 
(m.p. 69.0-74.0 oC) is a solid lipid based on glycerol esters of behenic acid (C22), where the main 
fatty acid is behenic acid > 85% but other fatty acids (C16-C20) are also present. Precirol ATO 5 
(m.p. 50.0-60.0 oC) and Geleol (m.p. 54.5-58.4 oC) are composed mainly of palmitic (C16) and stearic 
acid (C18) > 90 %. High melt temperature resulting in higher viscosity plus the long hydrocarbon 
chain length of Compritol 888 ATO might result in larger particle size compared to Precirol ATO 5 
and Geleol SLNs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. Effect of surfactant concentration on particle size measured by LD 90 % of different SLNs 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Effect of lipid concentration and type on particle size measured by LD 90 % of MLX SLNs 
 
Lipid concentration seems to be one of the most important factors influencing the particle 
size. According to Fig. 4, increasing the lipid content from 5, 7.5 to 10 % (w/w) resulted in a 
subsequent increase in particle size. It was noticeable that SLN11, SLN12, SLN17 and SLN18 
showed larger particle size exceeding the nanometer range. This increase in particle size may partially 
be related to the viscosity of the samples. The use of a low viscous lipid phase improves size 
reduction and enhances stability in SLN production (Manjunath et al., 2005). At higher lipid contents, 
the efficiency of homogenization decreases due to a higher viscosity of the sample, resulting in larger 
particles. Also, a high particle concentration at high lipid contents increases the probability of particle 
contact and subsequent aggregation (Freitas and Muller, 1998). 
Zeta potential analysis (ξ) and pH measurements 
 Table 2 shows the measured zeta potential (ξ) values of MLX SLNs. As depicted from the 
table, all formulations were negatively charged, the zeta potential varied from -17.6 to -38.6 mV 
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indicating a relatively good stability and dispersion quality. It was noticeable that as the amount of 
surfactant increased in the formulation, the zeta potential became more negative. A similar finding 
was previously reported upon increasing Tween 80 concentration from 0.5 to 1 % which was 
attributed to the formation of denser surfactant film (Estella-Hermoso de Mendoza et al., 2008). 
Poloxamer 188 being non-ionic surfactant succeeded in the production of relatively stable dispersions. 
Although non-ionic surfactant could not ionize into charging group like ionic ones, but still 
demonstrated its zeta potential. The reason might be due to molecular polarization and the adsorption 
of emulsifier molecule on the charge in water, it was absorbed to the emulsifier layer of particle/water 
interface and electric double layer similar to ionic was formed. Liu et al. reported that poloxamer 188 
was found to be one of the most effective non-ionic surfactants to avoid the formation of aggregates 
(Liu et al., 1996). Poloxamer 188 can provide additional steric stabilization of particles; so we can 
expect combined electrostatic and steric stabilization of SLN formulations (Schwarz and Mehnert, 
1999; Lim and Kim, 2002). 
 Considering the effect of lipid type and concentration on the zeta potential (ξ) of the produced 
SLN formulations, the results showed no direct relationship between the type of lipid used and the 
measured ξ values. On the contrary, as the lipid concentration increased the zeta potential was found 
to be more negative. Rahman et al. reported the same observation when studying the effect of 
increasing Compritol amount in final formulation (Rahman et al., 2010). 
 The pH of different MLX SLN formulations was found to be within acceptable limits for 
topical application ranging from 5.37 ± 0.02 to 6.39 ± 0.23 (table 2). 
Transmission Electron Microscopy (TEM) 
 TEM was conducted to investigate the morphology of MLX loaded SLNs. It was evident 
from TEM images that nanoparticles were almost spherical with smooth morphology, appeared as 
black dots, well dispersed and separated on the surface (Fig. 5). This description agrees with a 
previous observation that the use of chemically heterogeneous lipids in combination with 
heterogeneous surfactants favors the formation of ideally spherical lipid nanoparticles (Mehnert and 
Mader, 2001). Fig. 5d illustrates the presence of a very thin layer surrounding the particles which 
postulate a drug-enriched core model. This model can be achieved if during the lipid solidification 
process; the drug precipitates first, which results in a drug-enriched core covered with a lipid shell 
which has a lower drug concentration. This drug distribution within the nanoparticles will have its 
impact on in vitro drug release profile discussed later on. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5. Transmission electron micrographs of  MLX loaded SLN dispersions (a) SLN4 (b) SLN10 (c) SLN16 
and (d) SLN representing the core and shell theory 
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Differential scanning calorimetry (DSC) analysis  
 DSC is a tool to investigate the melting and recrystallization behavior of crystalline material 
like SLNs (Liu et al., 2005). Fig. 6 shows the DSC thermograms of pure MLX, bulk lipids (Geleol, 
Compritol 888 ATO and Precirol ATO 5) and MLX loaded SLNs. Pure MLX showed a sharp 
endothermic peak at 259.54 oC corresponding to its melting point, indicating its characteristic 
crystalline nature. Bulk Geleol showed distinctive melting peak at 66.01 oC, while a sharp peak at 
74.22 oC was observed for Compritol 888 ATO. The bulk Precirol ATO 5 exhibits a sharp 
endothermic event, ascribing to the melting, around 63.35 oC, with a small but well defined shoulder 
at 57.37 oC which might be due to the melting of α polymorphic form (Araujo et al., 2010). These 
sharp melting endothermic peaks of bulk lipids indicate that the starting materials were crystalline. As 
observed in Fig. 6, the thermograms of all investigated SLN systems did not show the melting peak of 
MLX around 259.54 oC indicating the conversion of crystalline MLX to the amorphous form which 
could be attributed to complete dissolution of the drug in the molten lipid matrix. The melting points 
of Geleol, Compritol 888 ATO and Precirol ATO 5 in SLN form were depressed showing slight shift 
to lower temperature side when compared to the corresponding bulk lipids. This melting point 
depression could be due to the small particle size (nanometer range), the high specific surface area, 
and the presence of surfactant - in other words, the depression can be attributed to the Kelvin effect 
(Jenning et al., 2000b). Kelvin realized that small, isolated particles would melt at a temperature lower 
than the melting temperature of bulk materials. In the same way, the melting enthalpy values of 
different lipids in SLN formulations showed drastic depression compared to their bulk lipids. These 
lower melting enthalpy values should suggest less ordered lattice arrangement of the lipid within 
nanoparticles compared to the bulk materials (Hou et al., 2003). For the less-ordered crystal or 
amorphous state, the melting of the substance requires less energy than the perfect crystalline 
substance, which needs to overcome lattice force. Lipid nanoparticles seem to loose part of their 
crystalline state transforming from a mixture of β' and β polymorphs to the most stable β polymorph, 
permitting MLX to fit in the molecular gaps. Therefore this decrease in the melting point and enthalpy 
values is associated with numerous lattice defects and the formation of amorphous regions in which 
the drug is located 
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Fig.6. DSC curves of pure drug (MLX), bulk lipids (Geleol, Compritol and Precirol) and MLX loaded SLNs 
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Rheological Study 
 As for other disperse liquid and semisolid systems, the rheological properties of lipid 
nanoparticles influence their potential for dermal application in a fundamental way (Muller et al., 
2002; Lippacher et al., 2001, 2002). Therefore, rheological behavior of different lipid nanoparticles 
formulations was studied and presented by plotting the shear stress versus shear rate (flow curves) and 
the viscosity versus the shear rate (viscosity curves) (Illinga and Unruh, 2004; Liu et al., 2008). The 
rheograms of different SLN formulations were shown in Fig. 7. 
 All SLN dispersions revealed non-Newtonian flow where the viscosity of non-Newtonian 
fluids changes according to the shear rate i.e. has no constant viscosity (49-Barnes, 1997). This flow 
was characterized by shear-thinning behavior in which the viscosity of the SLN dispersions decreased 
with the increase of shear rate. This dependent change in viscosity is a desired property in the 
pharmaceutical formulations due to their requirement of flexibility in topical drug delivery (50-Sheth, 
2007). When the preparation is subjected to a shear force, its network structure breaks down leading 
to a gradual decrease in viscosity in order to spread on the skin. When the shear force is removed, the 
viscosity recovers slowly and the increased viscosity keeps the preparation on the skin. 
 Comparing the viscosity curves of various SLN formulations, it was observed that, for each 
type of lipid, as the concentration of lipid increased the viscosity increased (Fig. 7). This may be 
related to the density of network structure, meaning that the network structure of 10 % (w/w) lipid 
was more viscous than that of 7.5 and 5 % (w/w) lipid, respectively, which was due to the higher 
amount of lipid incorporated into the system inducing an increase in the interaction between the lipid 
particles (Seetapan et al., 2010). In addition, the type of lipid affected the viscosity of the final 
product; Geleol SLNs showed lower viscosities compared to Precirol ATO 5 and Compritol 888 ATO 
SLNs. However, increasing the surfactant concentration did not result in considerable change in 
viscosity (data not represented). 
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Fig.7. Rheograms of (A) Geleol SLNs (B) Compritol SLNs (C) Precirol SLNs
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 In vitro Release Study 
 To elucidate the mechanism of MLX release from SLNs for topical administration, in vitro 
release study using dialysis bag diffusion technique has been performed over 48 hrs, each sample was 
analyzed in triplicate and the release curves are shown in Fig. 8. The release data was fitted into zero 
order, first order and Higuchi equations which are widely used in determining the release kinetics of 
lipid nanoparticles. The release pattern of the drug from almost all SLN formulations followed 
Higuchi equation with some fitted to zero order equation. The previous result is in agreement with 
many studies which reported that drug loaded SLN provide a controlled release pattern following 
Higuchi's square root model (Tiyaboonchai et al., 2007; Vivek et al., 2007).  
 As shown in Fig. 8, MLX SLN formulations were able to release MLX in controlled manner 
and the percentage of MLX released up to 48 hours ranged from 43.11% to 100%. Interestingly, the 
amount of poloxamer 188 used had a great influence on the release pattern of SLNs. Increasing the 
poloxamer 188 concentration from 0.5, 1, 2.5 to 5% (w/w) led to corresponding increase in the 
percentage of MLX released as well as the release efficiency % (R.E. %) after 48 h, which was 
noticeable for all three lipids used (Figs. 8 and 9). However, in case of Geleol (SLN1& SLN2) and 
Precirol ATO 5 (SLN13 & SLN14) no significant increase in R.E. % was found upon increasing 
poloxamer 188 concentration from 0.5 to 1 % (p>0.5%). The fast or rapid release and higher release 
efficiency noticed at higher surfactant concentration could be explained by the partitioning effects of 
the drug between the melted lipid phase and the aqueous surfactant phase during particle production. 
During particle production by the hot homogenization technique, drug partitions from the liquid oil 
phase to the aqueous water phase. The amount of drug partitioning to the water phase will increase 
with the increase of the drug solubility in the water phase, which means with increasing temperature 
of the aqueous phase and increasing surfactant concentration. The higher the temperature and 
surfactant concentration, the greater is the solubility of the drug in the water phase so the amount of 
drug in the outer shell increased and released in a relatively rapid way (Zur Muhlen and Mehnert, 
1998). 
 Concerning the type of lipid matrix, the results clearly show that among the glycerides used, 
the highest release was achieved with Geleol compared to Compritol 888 ATO and Precirol ATO 5. 
Being the lipid of highest monoglyceride content; Geleol had shown the highest release efficiency and 
consequently lower t50%, while in case of Compritol 888 ATO and Precirol ATO 5 the relatively slow 
release and higher t50% can be attributed to the hydrophobic long chain fatty acids of the triglycerides 
that retain the lipophilic drug resulting in more sustained release effect (Reddy and Murthy, 2005; 
Kumara et al., 2007) (Figs. 8-10). Furthermore, the lower melting point of Geleol (54.5-58.5oC) may 
result in a higher mobility at the temperature used in the release experiment. It is well known that the 
melting point of colloidal structures may be lower than that of the bulk due to the influence of surface 
energy (Mader, 2006). A difference in release profiles caused by a difference in lipid melting points 
was also suggested by Paolicelli et al. in a study with ibuprofen and acylglycerols differing in melting 
points (Paolicelli et al., 2009). The higher amount released from Geleol particles may also reflect the 
smaller size of these particles as the mean diameter of Geleol nanoparticles represent the smallest of 
the SLN tested.  
 The results also pointed to the effect of lipid concentration on SLNs release profile. 
Increasing the lipid concentration from 5, 7.5 to 10 % (w/w) resulted in a corresponding decrease in 
percentage of MLX released, R.E. % after 48 h and a consequent increase in t50% (Figs. 8-10). 
However, for Geleol and Precirol SLNs further increase of the lipid above 7.5% didn't result in a 
significant decrease in R.E. % (p>0.5%). This decrease in release profile observed can be attributed to 
the higher lipid content encapsulating the drug thus reducing drug partition in the outer phase and 
consequently its release in the receiver media. The release profiles of these SLNs resemble the drug 
enriched core model (Wissing et al., 2004). In such a model, the drug enriched core is surrounded by a 
practically drug-free lipid shell. Due to the increased diffusional distance and hindering effects by the 
surrounding solid lipid shell, the drug has a sustained release profile. 
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Fig.8. In vitro release percentage (%) - time profiles of MLX from SLNs. Data are expressed as the mean ± S.D. (n = 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9. Release efficiency (R.E. %) of different MLX SLNs formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.10. t 50 of different MLX SLNs formulations 
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Effect of storage on particle size  
 In order to evaluate the stability of lipid nanoparticles, the study of size was generally used as 
a characterization tool. The stability of the MLX loaded SLNs was studied for particle size after 12 
months of storage at 4 oC. As previously mentioned, LD 90% was used for comparing the change in 
particle size of different SLNs. 
 As illustrated in Fig. 11, SLNs prepared from different lipids showed non significant change 
in particle size indicating good stability during the period of study. No obvious change of clarity or 
degradation was observed. All samples were in the nanometer range except for SLN11, SLN12, 
SLN17 & SLN18 which was probably due to higher amounts of lipid added to these formulations 
leading to increment in viscosity and subsequent aggregation of the nanoparticles.   
 The increase in particle size was observed to be more pronounced at low surfactant 
concentration(  0.5-2.5% )  for the three surfactants used , while 5% SLN showed the highest stability 
and particle size was almost unchanged allover the course of this investigation. This good stability 
might be attributed to the strong repulsion by sterical stabilization of the surfactants used at higher 
concentration (Freitas and Muller, 1999), emphasizing the importance of surfactant concentration for 
SLN stabilization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11. Particle size measured by LD 90 % of MLX SLNs after 1 day and 12 months of storage at 4 oC  
 
It was noticeable that the role of surfactant in SLN systems varies depending on the lipid 
matrix used. SLN prepared with Geleol showed lower physical stability represented in higher 
percentage increase in particle size compared to Compritol 888 ATO and Precirol ATO 5. This could 
be explained by increased amount of partial glycerides like monoglycerides (40–55 % for Geleol, 15-
23 % for Compritol 888 ATO and 8-22 % for Precirol ATO 5) which might be responsible for this 
physical destabilization. These results are in agreement with those reported by Jenning and Gohla 
(Jenning and Gohla, 2000). 
Conclusion 
 In the present work, MLX-loaded SLNs were successfully prepared by high shear 
homogenization and ultrasonication technique.. The various physicochemical properties, rheological 
properties and the in vitro release behavior, were greatly affected and can be controlled by optimizing 
the compositional variables represented in the concentration of surfactant and lipid as well as the type 
of lipid used. The sustained release behaviour of MLX loaded SLNs with favourable physicochemical 
characteristics can form a foundation for further clinical studies using these nanoparticles for the 
topical delivery of meloxicam. 
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